No. |
Drug (Description in trials) |
DrugBank |
KEGG DRUG * |
KEGG GENES * [Number of genes] |
KEGG PATHWAY [Number of pathways] |
Disease ID * [Number of diseases] |
1 |
10-mg dose of e5501 2g tablet |
- |
- |
- |
- |
[1] 63 |
2 |
10-mg dose of e5501 cyclodextrin oral solution |
- |
- |
- |
- |
[1] 63 |
3 |
10-mg dose of e5501 lipid-based oral |
- |
- |
- |
- |
[1] 63 |
4 |
10-mg dose of e5501-p21% powder |
- |
- |
- |
- |
[1] 63 |
5 |
Akr-501 tablets |
- |
- |
- |
- |
[1] 63 |
6 |
Akr-501, ym-477 |
- |
- |
- |
- |
[1] 63 |
7 |
Alemtuzumab |
Alemtuzumab |
D02802 |
- |
- |
[13] 13, 15, 19, 20, 46, 51, 60, 63, 65, 85, 96, 164, 284 |
8 |
Alemtuzumab, rituximab |
Alemtuzumab |
D02802 |
- |
- |
[1] 63 |
9 |
All-trans retinoid acid(atra) |
Tretinoin |
D00094 |
[3] PML, RARA, RARB |
[12] Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Influenza A, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis |
[1] 63 |
10 |
Amg 531 |
- |
- |
- |
- |
[1] 63 |
11 |
Aminophylline |
Aminophylline |
D00227, D05429 |
[18] ADORA1, ADORA2B, PDE10A, PDE11A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE7A, PDE7B, PDE8A, PDE8B |
[23] Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[1] 63 |
12 |
Amoxicillin |
Amoxicillin |
D00229, D02925, D07452 |
- |
- |
[6] 6, 46, 63, 96, 97, 222 |
13 |
Amoxicillin hydrate |
Amoxicillin |
D00229, D02925, D07452 |
- |
- |
[1] 63 |
14 |
Amoxycillin |
Amoxicillin |
D00229, D02925, D07452 |
- |
- |
[1] 63 |
15 |
Anti-d |
- |
- |
- |
- |
[1] 63 |
16 |
Argx-113 |
- |
- |
- |
- |
[3] 11, 35, 63 |
17 |
Atorvastatin |
Atorvastatin |
D00258, D00887, D07474 |
[1] HMGCR |
[4] AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
[17] 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 160, 222, 225, 265, 271, 299 |
18 |
Atorvastatin 10mg |
Atorvastatin |
D00258, D00887, D07474 |
[1] HMGCR |
[4] AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
[1] 63 |
19 |
Atorvastatin 20mg |
Atorvastatin |
D00258, D00887, D07474 |
[1] HMGCR |
[4] AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
[1] 63 |
20 |
Atra |
Tretinoin |
D00094 |
[3] PML, RARA, RARB |
[12] Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Influenza A, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis |
[2] 63, 94 |
21 |
Avatrombopag |
Avatrombopag |
D10306 |
- |
- |
[1] 63 |
22 |
Avatrombopag (proposed) |
Avatrombopag |
D10306 |
- |
- |
[1] 63 |
23 |
Blinded (avatrombopoag tablets) |
- |
- |
- |
- |
[1] 63 |
24 |
Blisibimod |
Blisibimod |
D10311 |
- |
- |
[5] 43, 44, 49, 63, 66 |
25 |
Bms-986004 1500 mg iv |
- |
- |
- |
- |
[1] 63 |
26 |
Bms-986004 225 mg iv |
- |
- |
- |
- |
[1] 63 |
27 |
Bms-986004 675 mg iv |
- |
- |
- |
- |
[1] 63 |
28 |
Bms-986004 75 mg iv |
- |
- |
- |
- |
[1] 63 |
29 |
Bortezomib |
Bortezomib |
D03150 |
[1] PSMB5 |
[1] Proteasome |
[13] 11, 26, 28, 46, 49, 51, 61, 63, 66, 228, 256, 288, 331 |
30 |
Bt595 |
- |
- |
- |
- |
[2] 63, 65 |
31 |
Caffeic acid tablets |
- |
- |
- |
- |
[1] 63 |
32 |
Clarithromycin |
Clarithromycin |
D00276 |
- |
- |
[8] 6, 63, 84, 96, 97, 222, 228, 299 |
33 |
Conventional |
- |
- |
- |
- |
[1] 63 |
34 |
Corticosteroids (aprednislon) |
- |
- |
- |
- |
[1] 63 |
35 |
Cyclosporin |
Ciclosporin |
D00184 |
[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
[30] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
[16] 14, 38, 39, 49, 53, 56, 60, 62, 63, 97, 113, 164, 222, 223, 274, 326 |
36 |
Cyclosporin a |
Ciclosporin |
D00184 |
[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
[30] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
[11] 14, 38, 39, 49, 53, 56, 60, 62, 63, 113, 164 |
37 |
Decitabine |
Decitabine |
D03665 |
[3] DNMT1, DNMT3A, DNMT3B |
[3] Cysteine and methionine metabolism, Metabolic pathways, MicroRNAs in cancer |
[1] 63 |
38 |
Dexamethasone |
Dexamethasone |
D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[20] 13, 16, 28, 35, 46, 53, 63, 65, 70, 74, 75, 81, 83, 84, 90, 96, 97, 222, 296, 299 |
39 |
Dexamethasone (1 cycle) |
Dexamethasone |
D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[1] 63 |
40 |
Dexamethasone (4 cycles) |
Dexamethasone |
D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[1] 63 |
41 |
Dexamethasone abcur |
Dexamethasone |
D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[1] 63 |
42 |
Dexamethasone and rituximab |
Dexamethasone |
D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[1] 63 |
43 |
Doxil |
Doxorubicin |
D03899 |
[2] TOP2A, TOP2B |
[1] Platinum drug resistance |
[1] 63 |
44 |
E5501 |
- |
- |
- |
- |
[1] 63 |
45 |
E5501 - avatrombopag maleate |
Avatrombopag |
D10306 |
- |
- |
[1] 63 |
46 |
E5501 40 mg 2 x 20-mg tablets, orally, fasted |
- |
- |
- |
- |
[1] 63 |
47 |
E5501 40 mg 2 x 20-mg tablets, orally, with food |
- |
- |
- |
- |
[1] 63 |
48 |
E5501 40mg 2 x 20-mg tablets, orally, fasted |
- |
- |
- |
- |
[1] 63 |
49 |
Eltrombopag |
Eltrombopag |
D03978 |
- |
- |
[3] 60, 63, 285 |
50 |
Eltrombopag olamine (sb-497115-gr) |
Eltrombopag |
D03978 |
- |
- |
[1] 63 |
51 |
Eltrombopag oral tablets |
Eltrombopag |
D03978 |
- |
- |
[1] 63 |
52 |
Gammaplex, intravenous immunoglobulin |
Immune globulin human |
- |
- |
- |
[1] 63 |
53 |
Glycyrrhetinic acid |
- |
- |
- |
- |
[1] 63 |
54 |
Gma161 |
Gma161 |
- |
- |
- |
[1] 63 |
55 |
Hetrombopag olamine |
- |
- |
- |
- |
[2] 60, 63 |
56 |
High dose dexamethasone pulses |
Dexamethasone |
D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[1] 63 |
57 |
Huaiqihuang granule |
- |
- |
- |
- |
[1] 63 |
58 |
Human immunoglobulin |
- |
- |
- |
- |
[1] 63 |
59 |
Human immunoglobulin g |
Immune globulin human |
- |
- |
- |
[3] 14, 50, 63 |
60 |
Human normal immunoglobulin |
Immune globulin human |
- |
- |
- |
[8] 11, 13, 14, 43, 45, 50, 63, 65 |
61 |
Human normal immunoglobulin (iv) |
Immune globulin human |
- |
- |
- |
[4] 11, 14, 63, 65 |
62 |
Human normal immunoglobulin for intravenous use |
Immune globulin human |
- |
- |
- |
[2] 63, 65 |
63 |
Human normal immunoglobulin for intrvenous use |
Immune globulin human |
- |
- |
- |
[1] 63 |
64 |
Human normal immunoglobulin g (igg > 98% purity) |
Immune globulin human |
- |
- |
- |
[2] 14, 63 |
65 |
I10e |
- |
- |
- |
- |
[3] 14, 63, 65 |
66 |
Ig vena |
- |
- |
- |
- |
[2] 50, 63 |
67 |
Ig vena 100 ml vial |
- |
- |
- |
- |
[1] 63 |
68 |
Ig vena 50 g/l solution for infusion 100 ml vial + infusion set |
- |
- |
- |
- |
[2] 63, 65 |
69 |
Igg next generation |
- |
- |
- |
- |
[2] 63, 65 |
70 |
Igiv3i grifols 10% |
- |
- |
- |
- |
[1] 63 |
71 |
Ignextgen 10% |
- |
- |
- |
- |
[1] 63 |
72 |
Immune globulin intravenous |
Immune globulin human |
- |
- |
- |
[3] 14, 63, 65 |
73 |
Immune globulin intravenous (human), 10% triple virally reduced solution |
Immune globulin human |
- |
- |
- |
[1] 63 |
74 |
Immunglobulin |
- |
- |
- |
- |
[1] 63 |
75 |
Immunoglobulin g |
- |
- |
- |
- |
[7] 11, 13, 14, 49, 50, 63, 65 |
76 |
Inactivated trivalent influenza vaccine |
- |
- |
- |
- |
[1] 63 |
77 |
Interleukin 2 |
Human interleukin-2 |
- |
- |
- |
[9] 46, 49, 51, 56, 63, 95, 96, 97, 271 |
78 |
Intravenous immunoglobulin |
Immune globulin human |
- |
- |
- |
[16] 2, 11, 14, 17, 18, 35, 38, 39, 49, 51, 63, 65, 85, 164, 296, 309 |
79 |
Ivig |
Immune globulin human |
- |
- |
- |
[12] 11, 13, 14, 17, 18, 50, 51, 63, 65, 85, 164, 296 |
80 |
Ivig-l |
Immune globulin human |
- |
- |
- |
[1] 63 |
81 |
Lansoprazole |
Lansoprazole |
D00355 |
[2] ATP4A, ATP4B |
[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
[6] 63, 71, 98, 166, 222, 299 |
82 |
Lansoprazole, clarithromycin, amoxycillin |
Clarithromycin |
D00276 |
- |
- |
[1] 63 |
83 |
Liv-gamma sn inj. |
- |
- |
- |
- |
[1] 63 |
84 |
Mabthera |
- |
- |
- |
- |
[15] 11, 13, 35, 46, 50, 51, 53, 61, 63, 64, 65, 83, 162, 222, 271 |
85 |
Medical standard of care for itp |
- |
- |
- |
- |
[1] 63 |
86 |
Methylprednisolone |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[36] 2, 13, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 145, 164, 220, 222, 224, 271, 283, 284, 285, 296 |
87 |
Metronidazole |
Metronidazole |
D00409, D05016, D05017 |
- |
- |
[8] 46, 51, 63, 94, 95, 96, 97, 291 |
88 |
Nanogam |
- |
- |
- |
- |
[1] 63 |
89 |
Newgam |
- |
- |
- |
- |
[3] 14, 63, 65 |
90 |
Nplate |
Romiplostim |
D08990 |
[1] MPL |
[2] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway |
[1] 63 |
91 |
Null |
- |
- |
- |
- |
[17] 6, 13, 14, 15, 28, 37, 46, 49, 51, 63, 86, 90, 96, 97, 107, 145, 271 |
92 |
Octagam 10% |
- |
- |
- |
- |
[3] 50, 63, 65 |
93 |
Octagam® 10% |
- |
- |
- |
- |
[1] 63 |
94 |
Open label (avatrombopag tablets) |
Avatrombopag |
D10306 |
- |
- |
[1] 63 |
95 |
Palmitate |
Palmitic acid |
D05341 |
- |
- |
[1] 63 |
96 |
Pf-06755347 |
- |
- |
- |
- |
[1] 63 |
97 |
Prednisolone |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[38] 11, 13, 25, 26, 35, 38, 39, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
98 |
Prednisone |
Prednisone |
D00473 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[43] 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
99 |
Privigen® |
Immune globulin human |
- |
- |
- |
[2] 14, 63 |
100 |
Proteína recombinante estimulante de la megacariopoyesis |
- |
- |
- |
- |
[1] 63 |
101 |
Prtx-100 (staphylococcal protein a) |
Bevifimod |
- |
- |
- |
[1] 63 |
102 |
R788 |
- |
- |
- |
- |
[2] 46, 63 |
103 |
Recombinant human thrombopoietin (rhtpo) |
Thrombopoietin |
- |
- |
- |
[1] 63 |
104 |
Revolade |
Eltrombopag |
D03978 |
- |
- |
[2] 60, 63 |
105 |
Revolade, promacta |
Eltrombopag, Eltrombopag |
D03978 |
- |
- |
[1] 63 |
106 |
Rhtpo |
- |
- |
- |
- |
[2] 60, 63 |
107 |
Rhtpo in combination with rituximab |
Rituximab |
D02994 |
[1] MS4A1 |
[1] Hematopoietic cell lineage |
[1] 63 |
108 |
Rituximab |
Rituximab |
D02994 |
[1] MS4A1 |
[1] Hematopoietic cell lineage |
[42] 11, 13, 14, 17, 35, 36, 43, 44, 45, 46, 49, 50, 51, 52, 53, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 223, 229, 256, 271, 283, 284, 285, 288, 300, 331 |
109 |
Rituximab [mabthera/rituxan] |
Rituximab |
D02994 |
[1] MS4A1 |
[1] Hematopoietic cell lineage |
[2] 46, 63 |
110 |
Romiplostim |
Romiplostim |
D08990 |
[1] MPL |
[2] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway |
[2] 60, 63 |
111 |
Romiplostin |
- |
- |
- |
- |
[1] 63 |
112 |
Sb-497115 |
- |
- |
- |
- |
[1] 63 |
113 |
Sb-497115-gr 12.5mg |
- |
- |
- |
- |
[1] 63 |
114 |
Sb-497115-gr 25mg |
- |
- |
- |
- |
[1] 63 |
115 |
Sb-497115-gr 50 mg |
- |
- |
- |
- |
[1] 63 |
116 |
Sb497115 |
- |
- |
- |
- |
[2] 60, 63 |
117 |
Sirolimus |
Sirolimus |
D00753 |
[1] MTOR |
[43] AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
[30] 13, 17, 34, 35, 36, 46, 51, 60, 62, 63, 65, 66, 67, 85, 89, 96, 98, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 285, 331 |
118 |
Sm101 |
- |
- |
- |
- |
[3] 49, 63, 66 |
119 |
Staphylococcal protein a |
Bevifimod |
- |
- |
- |
[1] 63 |
120 |
Steroids |
- |
- |
- |
- |
[7] 46, 50, 51, 63, 66, 96, 97 |
121 |
Takecab tablets + amoxicillin + clarithromycin (first-line eradication) takecab tablets + amoxicillin + metronidazole (second-line eradication) |
Clarithromycin |
D00276 |
- |
- |
[1] 63 |
122 |
Thrombopoietin |
Thrombopoietin |
- |
- |
- |
[3] 47, 60, 63 |
123 |
Triple therapy |
- |
- |
- |
- |
[1] 63 |
124 |
Tysabri |
Natalizumab |
D06886 |
[1] ITGA4 |
[14] Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
[3] 13, 25, 63 |
125 |
Ucb7665 |
- |
- |
- |
- |
[2] 11, 63 |
126 |
Vonoprazan |
Vonoprazan |
- |
- |
- |
[2] 63, 98 |
127 |
Water |
Water |
D00001 |
- |
- |
[18] 2, 5, 6, 13, 17, 19, 35, 46, 53, 57, 63, 65, 67, 84, 97, 226, 278, 299 |